Back to results
US 2026/0284114 A1Published application
Method for producing milk like products
AssigneeSociete des Produits Nestle S.A.
InventorsOmid MASHINCHIAN, Marine KRAUS, Charith HETTIARACHCHI, Loïc DAYON, Francesca GIUFFRIDA, Alix ZOLLINGER, Solenn PRUVOST, Lucile YART, Laurent FERRIER
Life of this patent
Estimating the term…
Abstract
A method of producing mammalian breast milk exosomes, for example human breast milk exosomes comprising generating lactocytes derived from mammalian mammary epithelial cells, for example human mammary epithelial cells, expressing the mammalian milk like product, for example the human milk like product from lactocytes, and purifying the exosomes from the mammalian milk like product.
Claims29
1:
- An isolated human breast milk exosome, wherein Hypoxia up-regulated protein 1 (HYOU1), Apolipoprotein A-IV (APOA4) and Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD1) are not detected by liquid chromatography—mass spectrometry in the isolated human breast milk exosome.
2:
- The isolated human breast milk exosome of claim 1, wherein C4a anaphylatoxin (CFA), Hypoxia up-regulated protein 1 (HYOU1), Apolipoprotein A-IV (APOA4), Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD1), Threonine—tRNA ligase 1, cytoplasmic (TARS1), and Cytosolic non-specific dipeptidase (CNDP2) are not detected by liquid chromatography—mass spectrometry in the isolated human breast milk exosome.
3:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome comprises lactotransferrin (LTF), annexin A2 (ANXA2) and lactadherin (MFGE8), MUC1 and tetraspanins CD9, CD81 and CD63.
4:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome comprises one or more miRNAs selected from the group consisting of miR-148a-3p, miR-22-3p, miR-125b-5b and miR-6126.
5:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome comprises one or more lipids selected from the group consisting of cholesterol esters, ceramides, triacylglycerides, diacylglycerides, lyso-phospholipids, total phospholipids, alkanyl phospholipids, and alkenyl phospholipids.
6:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome comprises one or more phospholipids selected from the group consisting of sphingomyelins, phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine.
7:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome has a diameter of 50 to 100 nm.
8:
- The isolated human breast milk exosome of claim 7, wherein the isolated human breast milk exosome has a diameter size of 65 to 75 nm.
9:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome has the same function as exosomes derived from natural human breast milk.
10:
- The isolated human breast milk exosome of claim 1, wherein the isolated human breast milk exosome has the same structure as exosomes derived from natural human breast milk.
11:
- A population of exosomes, wherein the population comprises an isolated human breast milk exosome in which Hypoxia up-regulated protein 1 (HYOU1), Apolipoprotein A-IV (APOA4) and Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD1) are not detected by liquid chromatography—mass spectrometry.
(canceled)
13:
- An in vitro method for producing an isolated human breast milk exosome, the method comprising:
- A) Culturing mammary epithelial cells in a culture medium to generate lactocyte mammary-like gland organoids;
- and
- B) Secreting a mammalian milk like product from the lactocyte mammary-like gland organoids, and
- C) Purifying exosomes from the mammalian milk like product to remove impurities, in order to isolate the exosomes.
2 more elements
14:
- The method of claim 13, wherein the time duration of step A) is no longer than 14 days.
15:
- The method of claim 13, wherein Step A) is conducted in 3D suspension culture conditions.
16:
- The method of claim 13, wherein step C) further comprises formulating the isolated exosomes into a powder form or liquid form.
17:
- The method of claim 13, wherein step C) further comprises sterilising the isolated exosomes.
18:
- The method of claim 13, wherein step C) further comprises storing the isolated exosomes at below freezing.
19:
- The method of claim 13, further comprising formulating the isolated exosomes with supplementary nutritional ingredients.
20:
- The method of claim 13, wherein the isolated exosomes are dispensed into a container for consumption.
21:
- A human breast milk exosome product which is obtainable according to the method of claim 13.
22:
- A method of producing a human milk fortifier, comprising conducting the method of claim 13.
(canceled)
24:
- A method of treating a disease or disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated human breast milk exosome in which Hypoxia up-regulated protein 1 (HYOU1), Apolipoprotein A-IV (APOA4) and Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD11) are not detected by liquid chromatography—mass spectrometry.
25:
- A method of preventing, treating, or ameliorating symptoms associated with inflammation, the method comprising administering to a subject in need thereof a therapeutically effective amount of an isolated human breast milk exosome in which Hypoxia up-regulated protein 1 (HYOU1), Apolipoprotein A-IV (APOA4) and Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 (PLOD1) are not detected by liquid chromatography—mass spectrometry.
(canceled)
27:
- The method of claim 25, wherein the inflammation is at least one of intestinal inflammation, bronchial inflammation or respiratory inflammation.
(canceled)
(canceled)
Dependencies are inferred from the claim text.